Hong Kong’s Clearing Limited (HKEX) have announced its plans to launch future fulfillment of the Seng Biotech index.
The new contract of future fulfillment, which begins the negotiation on November 28, 2025, is based on the Hang Seng Biotech index.
The Hang Seng Biotech index monitors the performance of the 30 largest biotechnological, pharmaceutical and medical devices eligible from the southern reserve, pharmaceutical and medical devices. The future will provide investors with a targeted risk management tool for one of the fastest growing and more dynamic areas, complementing the existing biotechnology -related suite and derivatives.
Hkex market chief Gregory Yu said:
“Promoted by innovation and strong global health care demand, the biotechnology industry is one of the most exciting border in capital markets today. We are pleased to start the Hang Seng Biotech Futures Futures, which extend the access of investors to contributing to the development of the region’s Biotech Ecosystem.
Since Hkex Reforms in 2018, Biotech and Healthcare have emerged as one of the most active areas in Hong Kong capital markets. Today, over 260 biotechnology and healthcare companies are listed in HKEX, representing a combined market capitalization of more than $ 4.8 trillion – increased by $ 400% from about $ 1.2 trillion at the end of 2018.
The Mobile and Future Fulfillment Committee will resign for the first six months of negotiating new contracts. The margins will be announced in due time.